Season 2024 Episode 528
Discover how this Nordic-US investment accelerator is transforming early-stage life sciences companies and creating unique opportunities in multibillion-dollar markets.
In this exclusive interview, Henrik Rouf, CEO of Nordicus Partners (OTCQB: NORD), discusses the company's unique approach to accelerating Nordic life sciences companies into the US market. With decades of combined experience, their team identifies and develops promising biotech opportunities, focusing on treatments for diseases with significant unmet medical needs. Henrik shares insights on their current portfolio companies, Orocidin and Bio-Convert ApS, their strategic position bridging Nordic innovation with US market opportunities, and their debt-free growth strategy.
Learn more about Nordicus Partners: https://nordicuspartners.com/
Watch the full YouTube interview here: https://youtu.be/98BfFBNOgmo
And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1
Published on 11 months, 3 weeks ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate